Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Alligator Bioscience AB (publ)
  6. News
  7. Summary
    ATORX   SE0000767188

ALLIGATOR BIOSCIENCE AB (PUBL)

(ATORX)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 12/01 11:29:45 am
2.29 SEK   +2.46%
02:31aAlligator announces final outcome of rights issue
AQ
11/29Alligator announces preliminary outcome of rights issue
AQ
11/12Alligator Bioscience Starts $29 Million Rights Issue
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Alligator Bioscience AB: Correction regarding MAR marking

10/21/2021 | 08:44am EST

The press release as of October 21, 2020 regarding the Interim report January - September 2021 incorrectly contained a so-called MAR marking. This was not the company's intention, as the information is not to be regarded as inside information.

For further information, please contact:

Julie Silber, Investor Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The pipeline includes two clinical assets: mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Alligator Bioscience is co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and an undisclosed molecule based on its proprietary Neo-X-Prime™ technology platform with MacroGenics Inc. Outlicensed programs include AC101 in clinical development by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.  Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX). Alligator is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.

https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab--correction-regarding-mar-marking,c3437717

https://mb.cision.com/Main/12681/3437717/1484326.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about ALLIGATOR BIOSCIENCE AB (PUBL)
02:31aAlligator announces final outcome of rights issue
AQ
11/29Alligator announces preliminary outcome of rights issue
AQ
11/12Alligator Bioscience Starts $29 Million Rights Issue
MT
11/12Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 202..
AQ
11/12Alligator Bioscience AB Announces New Preclinical Data Highlighting the 4-1Bb Antibody ..
CI
11/12Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the le..
AQ
11/12Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 20..
AQ
11/12The subscription period in Alligator Bioscience's rights issue begins today
AQ
11/10Alligator Bioscience to Participate in Upcoming Investor Conferences
PU
11/09Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
AQ
More news
Financials
Sales 2021 10,6 M 1,17 M 1,17 M
Net income 2021 -143 M -15,8 M -15,8 M
Net cash 2021 300 M 33,0 M 33,0 M
P/E ratio 2021 -1,40x
Yield 2021 -
Capitalization 196 M 21,7 M 21,6 M
EV / Sales 2021 -9,72x
EV / Sales 2022 17,8x
Nbr of Employees 44
Free-Float 89,4%
Chart ALLIGATOR BIOSCIENCE AB (PUBL)
Duration : Period :
Alligator Bioscience AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLIGATOR BIOSCIENCE AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 2,29 SEK
Average target price 2,60 SEK
Spread / Average Target 13,5%
EPS Revisions
Managers and Directors
S°ren Bregenholt Chief Executive Officer
Marie Svensson Chief Financial Officer
Anders Olof Adolf Ekblom Chairman
Peter Ellmark Chief Scientific Officer
Christina Reimer Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLIGATOR BIOSCIENCE AB (PUBL)-68.01%21
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
IQVIA HOLDINGS INC.44.63%49 504
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-41.09%23 827